Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Dysfunction and Ischemia-Reperfusion Injury Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCDC109A/MCU drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCDC109A/MCU Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for immunization and structural studies. |
View CCDC109A Products |
| Gene Delivery | CCDC109A/MCU Promise-ORF / Lentivirus Full-length ORF lentiviral particles optimized for stable cell line generation. Ideal for functional calcium flux assays. |
View CCDC109A Products |
| Benchmark Ab | Anti-CCDC109A Recombinant Antibody Recombinant positive control antibody for target validation, Western Blot, and IHC. |
View CCDC109A Products |
| Validator | CCDC109A siRNA Set Target-specific siRNA pool for efficient knockdown verification in functional assays. |
View CCDC109A Products |
| Related Target A | MICU1 Mitochondrial calcium uptake regulator 1. Essential gatekeeper regulating MCU channel activity. |
View MICU1 Products |
| Related Target B | SMDT1 Single-pass membrane protein (EMRE). Essential mediator for MCU channel opening and calcium transport. |
View SMDT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane structure limits soluble protein utility in functional assays. | High-titer Lentivirus Premade Particles to construct stable cell lines for live-cell calcium imaging. |
| Complex oligomeric assembly (MCU-MICU1-EMRE) requires co-expression. | Sequence-verified ORF and lentiviral clones for all complex subunits to enable co-transduction. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CCDC109A/MCU R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCDC109A/MCU therapeutics is intensifying, with major players shifting focus from traditional academic probes to highly selective small molecule inhibitors and gene therapy modalities. As first-generation therapies target acute indications like myocardial ischemia-reperfusion injury, the next wave of R&D is targeting chronic neurodegenerative diseases and metabolic syndromes where mitochondrial calcium overload drives pathology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Ischemia-Reperfusion Injury, Stroke | Mitochondrial Calcium Flux Assay (Need Lentivirus for Stable Cell Lines) |
| Gene Therapy (RNAi/AAV) | Preclinical Biotechs | Huntington's, Alzheimer's Disease | Target Knockdown Validation (Need Sequence-Verified siRNA & Antibodies) |
| Peptide Therapeutics | Translational Research Institutes | Heart Failure, Muscle Dystrophy | Protein-Protein Interaction Assays (Need MCU/MICU1 Soluble Domains) |